Previous Close | 1.0000 |
Open | 0.9000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 2.50 |
Expire Date | 2024-06-21 |
Day's Range | 0.9000 - 1.0000 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
Despite a Net Loss, Codexis Demonstrates Strong Revenue Growth and Strategic Milestones
Q1 Total Revenue Up 32% Year-over-year, Including Product Revenue Up 14%; Company Reiterates 2024 Financial Guidance First Substantial Order for dsRNA Ligase Received from Large Pharma Customer Company is in Final Stages of Enzymatically Synthesizing a Full-Length Oligonucleotide with ECO Synthesis™ Manufacturing Platform and will Provide Update at TIDES USA Meeting REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today an
Key Insights Given the large stake in the stock by institutions, Codexis' stock price might be vulnerable to their...